Business Description
Nuvalent Inc
NAICS : 325412
SIC : 2834
ISIN : US6707031075
Share Class Description:
NUVL: Class ADescription
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.96 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -51.5 | |||||
| 3-Year EPS without NRI Growth Rate | -50.5 | |||||
| 3-Year FCF Growth Rate | -37.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 15.1 | |||||
| 9-Day RSI | 21.41 | |||||
| 14-Day RSI | 26.9 | |||||
| 6-1 Month Momentum % | 47.24 | |||||
| 12-1 Month Momentum % | 148.68 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 22.83 | |||||
| Quick Ratio | 22.83 | |||||
| Cash Ratio | 22.62 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -41 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -26.03 | |||||
| ROA % | -24.82 | |||||
| ROIC % | -1583.07 | |||||
| ROCE % | -30.83 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 5.74 | |||||
| Price-to-Tangible-Book | 5.74 | |||||
| EV-to-EBIT | -22.18 | |||||
| EV-to-EBITDA | -22.18 | |||||
| EV-to-FCF | -33.24 | |||||
| Price-to-Net-Current-Asset-Value | 5.79 | |||||
| Price-to-Net-Cash | 5.84 | |||||
| Earnings Yield (Greenblatt) % | -4.51 | |||||
| FCF Yield % | -2.48 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NUVL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nuvalent Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.16 | ||
| Beta | 0 | ||
| Volatility % | 47.68 | ||
| 14-Day RSI | 26.9 | ||
| 14-Day ATR ($) | 3.02536 | ||
| 20-Day SMA ($) | 70.9735 | ||
| 12-1 Month Momentum % | 148.68 | ||
| 52-Week Range ($) | 32.06 - 89.39 | ||
| Shares Outstanding (Mil) | 64.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nuvalent Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nuvalent Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Nuvalent Inc Frequently Asked Questions
What is Nuvalent Inc(NUVL)'s stock price today?
The current price of NUVL is $62.76. The 52 week high of NUVL is $89.39 and 52 week low is $32.06.
When is next earnings date of Nuvalent Inc(NUVL)?
The next earnings date of Nuvalent Inc(NUVL) is 2024-05-10 Est..
Does Nuvalent Inc(NUVL) pay dividends? If so, how much?
Nuvalent Inc(NUVL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers